Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GA Depot in Relapsing Forms of Multiple Sclerosis
NCT04121221Phase 3Completed
- Sponsor
- Mapi Pharma
- Start
- Sep 2019
- Primary completion
- Jun 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing GA Depot with Placebo (2 arms). Primary endpoint: Annualized Relapse Rate at 52 weeks. Started Sep 2019; status: completed.
02
Drugs
glatiramer acetate depot
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04121221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04121221.